1. Clinical Evaluation of Efficacy and Tolerability of HMC05 in Healthy Subjects with Normal and High-Normal Blood Pressure: A Pilot Study.
- Author
-
Hae Won Lee, Mi-sun Lim, Sook Jin Seong, Jeonghyeon Park, Joomi Lee, Jeong Ju Seo, Sung-Doo Kim, Heung-Mook Shin, and Young-Ran Yoon
- Subjects
- *
BLOOD pressure , *HYPERTENSION , *VASODILATION , *C-reactive protein , *HOMOCYSTEINE , *PLANT extracts , *CROSSOVER trials , *PLACEBOS , *EVALUATION , *HEART beat , *HIGH performance liquid chromatography , *KOREANS , *MASS spectrometry , *MEDICINAL plants , *ORAL drug administration , *HEALTH outcome assessment , *RESEARCH funding , *STATISTICS , *T-test (Statistics) , *DRUG tablets , *PILOT projects , *DATA analysis , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *DATA analysis software ,THERAPEUTIC use of plant extracts - Abstract
HMC05, a formulation containing eight different herbal extracts, has been used widely for several thousand years in China, Japan, and Korea as a remedy for hypertension and headache. Although its anti-inflammatory effects in mouse monocytic cell lines and anti-atherosclerotic effects in apoEknockout mice have been reported, the pharmacodynamic effects of HMC05 in human subjects have not yet been investigated. We evaluated the efficacy and tolerability of this drug in 14 healthy male Korean subjects with normal or high-normal blood pressure (BP) in a randomized, singleblind, crossover study with a 2-week washout period. Four 500-mg tablets of HMC05 or placebo were orally administered three times daily to nine subjects with normal BP and five subjects with high-normal BP for 4 weeks. To assess the pharmacodynamic effects of HMC05, levels of highsensitivity C-reactive protein and homocysteine, BP, and flow-mediated vasodilation were measured before and after the 4-week medication period with evaluation of tolerability. All 14 subjects completed the study, and HMC05 was well tolerated with no significant adverse events. HMC05 did not exhibit a significant BP-lowering effect in either BP group, and therewere no significant differences in other pharmacodynamic values after HMC05 or placebo administration in the two groups. Further study is needed to evaluate the efficacy and tolerability of HMC05 in an adequate number of patients with hypertension. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF